Greenspace Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Collaborative care platform for mental health measurement and outcomes tracking, Toronto Canada. Helps health systems use data to improve patient mental health outcomes.
About
Greenspace Health is a Toronto, Canada-based digital health company founded in 2015 that provides a collaborative care platform designed to embed measurement-based care practices into mental health and primary care settings. The platform enables clinicians and care teams to systematically collect, track, and act on patient-reported outcome measures (PROMs), bringing data-driven decision-making to mental health treatment in a way that mirrors how chronic disease management is handled in other medical specialties.\n\nThe Greenspace platform supports the collection of validated clinical measurement tools such as the PHQ-9 (depression), GAD-7 (anxiety), and dozens of other standardized instruments, delivered to patients via mobile or web between sessions. Clinicians receive visualized outcome trends, alerts for deteriorating patients, and population-level dashboards that allow managers to identify care gaps and resource needs. The system is designed to integrate with existing EHRs and fit into existing clinical workflows rather than replace them.\n\nGreenspace primarily serves health systems, community mental health centers, and primary care organizations in Canada and the United States that are implementing collaborative care models or value-based mental health contracts. As payers and government health agencies increase pressure on providers to demonstrate mental health treatment outcomes, Greenspace is positioned as essential infrastructure for outcomes accountability. The company has partnered with several provincial health systems in Canada and is expanding its US footprint through health system partnerships.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.